P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB.

Authors :: Nakamura, R.
Hendricks, R.
Dokhaei, R.
Susilo, M.
Wilson, D.
Trudel, S.
Cohen, A.
Harrison, S. J.
Krishnan, A.
Fonseca, R.
Adamkewicz, J. I.
Li, M.
Wong, C.
Cooper, J.
Sumiyoshi, T.
Source :: HemaSphere; 2022 Supplement 3, Vol. 6, p852-853, 2p
Publication Year :: 2022

Full Text Access

Tools